SCHEMBL19149031

SCHEMBL19149031

CC(C)(C)OC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3cnccc32)C1

nearest known ligand 0.74

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BTK Q06187 19/20 0.74
EGFR P00533 1/20 0.73
LCK P06239 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19149030 1.00 BTK (0.74) BTKEGFRLCK
SCHEMBL19149789 0.89 BTK (0.81) BTKEGFRLCK
SCHEMBL19149790 0.89 BTK (0.81) BTKEGFRLCK
SCHEMBL19150688 0.89 BTK (0.67) BTKEGFRLCK
SCHEMBL19150689 0.89 BTK (0.67) BTKEGFRLCK
SCHEMBL19148587 0.88 BTK (0.71) BTKEGFRLCK
SCHEMBL22018928 0.88 EGFR (0.79) BTKEGFRLCK
SCHEMBL28691174 0.88 BTK (0.71) BTKEGFRLCK
SCHEMBL19149014 0.88 BTK (0.68) BTKEGFRLCK
SCHEMBL19149013 0.88 BTK (0.68) BTKEGFRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3405192-B1 BRUTON'S TYROSINE KINASE INHIBITORS ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) 2024-12-11 EP disclosed
CN-109310671-B Bruton's tyrosine kinase inhibitors 淄博百极常生制药有限公司 2021-08-06 CN disclosed
US-10793566-B2 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) 2020-10-06 US disclosed
US-10793566-B2 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) 2020-10-06 US disclosed
US-10662187-B2 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) 2020-05-26 US disclosed
US-10662187-B2 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) 2020-05-26 US disclosed
US-20190276453-A1 BRUTON'S TYROSINE KINASE INHIBITORS SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-09-12 US disclosed
US-20190276453-A1 BRUTON'S TYROSINE KINASE INHIBITORS SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-09-12 US disclosed
EP-3405192-A1 BRUTON'S TYROSINE KINASE INHIBITORS Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. (CN) 2018-11-28 EP disclosed
WO-2017127371-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNNYLIFE PHARMA INC. (US) 2017-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662187-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK BTK 1/4885EGFR 210/4885LCK 5/4885
US-10793566-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK BTK 1/4885EGFR 210/4885LCK 5/4885
US-20190276453-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK BTK 1/4885EGFR 210/4885LCK 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.